The research focus of the Telethon Kids Cancer Centre is on developing safe new treatments for the deadliest childhood cancers - brain cancer, sarcoma, leukaemia and neuroblastoma.
The research of the Telethon Kids Cancer Centre is undertaken by laboratory-based scientists, paediatric oncologists, computational biologists, and many higher degree (mainly PhD) and Honours students. Our research is organised into collaborative programs of laboratory-based and translational research.
Our goal is to discover new therapies - therapies that are more effective and less toxic - to fight the most aggressive cancers in babies and children. Our research focuses on:
Harnessing the power of the body's own immune system to fight cancer cells via immunotherapy.
Determining why apparently similar cancer cells from individual patients respond differently to treatment.
Testing existing drugs and new compounds to improve patient outcomes.
Understanding the biology of individual cancers to identify weaknesses to target with therapies.
Developing new treatments with industry partners to feed our drug development pipeline.
The Telethon Kids Cancer Centre has a game changing approach for fighting childhood cancer
Our research strategy is to use our world-first childhood cancer laboratory models to investigate potential new cancer immunotherapies and personalised medicines.
Immunotherapy is an exciting cancer treatment that works by engaging the body’s own immune response to fight the cancer. It promises to be an effective and safe cancer therapy that does not cause the collateral damage of conventional treatments. Immunotherapy has fulfilled this promise for adults with extraordinary results in some cancers. Sadly, the development of immunotherapy treatments for children falls far behind.
Personalised medicine involves performing detailed genetic analysis of individual children with cancer and using the information gained to treat them with drugs that are precisely targeted to the individual tumour. All children with cancer treated in Perth undergo such genetic testing, allowing us to use the genetics of individual’s tumours to inform both treatment development in the laboratory and clinical trial opportunities on the ward.
Our goal is to develop such promising and safe treatments to defeat childhood cancers and reduce the need for toxic chemotherapies and radiotherapies.
If you are interested in potential research collaborations, please contact us.
In this Commentary article, as part of the 100-year celebrations of the journal, we reflect on the contribution of articles published in ICB in the field of tumor immunology. A highlight is a series of interviews conducted with three Australian-based ICB authors who have contributed key papers over the years: Rajiv Khanna, Delia Nelson and Ian Frazer.
DNA methylation array profiling for classifying pediatric central nervous system (CNS) tumors is a valuable adjunct to histopathology. However, unbiased prospective and interlaboratory validation studies have been lacking. The AIM BRAIN diagnostic trial involving 11 pediatric cancer centers in Australia and New Zealand.
Although recent studies have demonstrated associations between nonchromosomal birth defects and several pediatric cancers, less is known about their role on childhood leukemia susceptibility. Using data from the Childhood Cancer and Leukemia International Consortium, we evaluated associations between nonchromosomal birth defects and childhood leukemia.
The Toronto Paediatric Cancer Stage Guidelines are a compendium of staging systems developed to facilitate collection of consistent and comparable data on stage at diagnosis for childhood cancers by cancer registries.